Table 2.
Cox regression multivariable analysis of clinical baseline and on-treatment prognostic factorsa.
| Variable | OS HR (95% CI) |
p-Value | rPFS HR (95% CI) |
p-Value |
|---|---|---|---|---|
| Age a, median, years | - | - | ||
| <78 | 1.00 (ref) | 0.008 | ||
| ≥78 | 2.47 (1.27–4.79) | |||
| Geriatric G8, median | ||||
| >14 | 1.00 (ref) | 1.00 (ref) | ||
| ≤14 | 3.10 (1.43–6.74) | 0.004 | 2.39 (1.46–3.91) | <0.001 |
| PSA50 | ||||
| No | 1.00 (ref) | 1.00 (ref) | ||
| Yes | 0.14 (0.07–0.25) | <0.001 | 0.29 (0.18–0.46) | <0.001 |
| Gleason score, median | - | - | ||
| ≥8 | 1.00 (ref) | |||
| <8 | 0.82 (0.49–1.38) | 0.457 | ||
| Surgery at diagnosis | - | - | ||
| Yes | 1.00 (ref) | |||
| No | 1.38 (0.87–2.21) | 0.173 | ||
| Time to CR, mo, median | - | - | ||
| <31 | 1.00 (ref) | |||
| ≥31 | 2.30 (1.46–3.64) | <0.001 | ||
| Sites of metastases a | - | - | ||
| Bone (non-visceral) | 1.00 (ref) | |||
| Lymph nodes (only) | 0.51 (0.23–1.11) | 0.090 | ||
| Visceral | 0.90 (0.46–1.76) | 0.748 | ||
| Setting of therapy | - | - | ||
| Post-chemotherapy | 1.00 (ref) | |||
| Pre-chemotherapy | 0.69 (0.42–1.15) | 0.157 | ||
| Post-Abi/Enza | 4.31 (1.42–13.04) | 0.010 | ||
| Charlson score, median | - | - | ||
| ≥9 | 1.00 (ref) | |||
| <9 | 0.61 (0.34–1.11) | 0.109 | ||
| Caregiver | - | - | ||
| Yes | 1.00 (ref) | |||
| No | 0.69 (0.36–1.31) | 0.251 | ||
| Treatment | - | - | ||
| Enza | 1.00 (ref) | |||
| Abi | 0.75 (0.46–1.19) | 0.221 |
Abbreviations: Abi, abiraterone; BM, bone metastases (non-visceral); ChT, chemotherapy; CI, confidence intervals; CR, castration resistance; Enza, enzalutamide; HR, hazard ratio; LN, lymphnodes; No. Number; OS, overall survival; PSA50, decline in the PSA ≥ 50%; ref, reference; rPFS, radiographic progression-free survival; Tx, treatment. a Only for variables with a p-value < 0.05 at univariable analysis. Statistically significant values in bold (p < 0.005).